Myriad Genetics, Inc. (MYGN)
After hours: 01:02PM EST
| Previous Close | 27.47 |
| Open | 27.08 |
| Bid | 13.00 x 900 |
| Ask | 33.44 x 800 |
| Day's Range | 26.36 - 27.67 |
| 52 Week Range | 17.18 - 36.95 |
| Volume | 387,997 |
| Avg. Volume | 428,487 |
| Market Cap | 2.125B |
| Beta (5Y Monthly) | 1.51 |
| PE Ratio (TTM) | 34.20 |
| EPS (TTM) | 0.78 |
| Earnings Date | Feb. 21, 2022 - Feb. 25, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.25 |
- GlobeNewswire
The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults
GeneSight Mental Health Monitor finds many parents struggle to know the difference between teenage behavior and a mental health challengeSALT LAKE CITY, Nov. 23, 2021 (GLOBE NEWSWIRE) -- One of the biggest issues parents of teenagers may face is determining if their child is experiencing a mental health challenge or ordinary “growing pains.” Only half of parents* with children ages 16 to 24 said they are very or completely confident they can tell the difference between normal adolescent challeng
- GlobeNewswire
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment
SALT LAKE CITY, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two upcoming poster presentations at the 2021 San Antonio Breast Cancer Symposium (SABCS) that showcase the importance of genetic testing and precision medicine as integral components of both breast cancer treatment recommendations and risk assessment. “These studies demonstrate our ongoing commitment to excellence in scientific research and
- Zacks
Myriad Genetics (MYGN) Q3 Loss Wider Than Expected, Revenues Top
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.
